AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 32701208 — intervention group
Group type: EXPERIMENTAL
Intervention: Severe RAPD or visual acuity (VA) < 35 letters (ETDRS) at inclusion or at one month
Number of subjects: 101
Study 32701208 — intervention group
Group type: EXPERIMENTAL
Intervention: RAPD assessment
Number of subjects: 101
Study 32767988 — intervention group
Group type: EXPERIMENTAL
Intervention: Mastectomy combined with flap fixation and closed-suction drainage
Number of subjects: 250
Study 32767988 — intervention group
Group type: COMPARATOR
Intervention: Mastectomy combined with flap fixation without drainage
Number of subjects: 250
Study 34699409 — intervention group
Group type: EXPERIMENTAL
Intervention: Vibegron 75 mg once daily for 28 days
Number of subjects: 214
Study 34699409 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 214
Study 34069892 — intervention group
Group type: EXPERIMENTAL
Intervention: 3 mg/kg caffeine
Number of subjects: 16
Study 35372547 — intervention group
Group type: EXPERIMENTAL
Intervention: Alveolar recruitment maneuver (ARM)
Number of subjects: 21
Study 35372547 — intervention group
Group type: COMPARATOR
Intervention: PEEP (5 cmH2O)
Number of subjects: 21
Study 32446842 — intervention group
Group type: EXPERIMENTAL
Intervention: Cooling anesthesia at -10° C
Number of subjects: 22
Study 32446842 — intervention group
Group type: COMPARATOR
Intervention: Standard of care (SOC) lidocaine-based anesthesia
Number of subjects: 22
Study 32446842 — intervention group
Group type: EXPERIMENTAL
Intervention: Cooling anesthesia
Number of subjects: 22
Study 32446842 — intervention group
Group type: COMPARATOR
Intervention: Standard of care (SOC)
Number of subjects: 22
Study 34756414 — intervention group
Group type: EXPERIMENTAL
Intervention: Vacuum sealing drainage (VSD)
Number of subjects: 120
Study 34756414 — intervention group
Group type: COMPARATOR
Intervention: Conventional drainage
Number of subjects: 120
Study 32935921 — intervention group
Group type: EXPERIMENTAL
Intervention: Flash Glucose Monitoring (FGM)
Number of subjects: 64
Study 32935921 — intervention group
Group type: COMPARATOR
Intervention: Self-Monitored Blood Glucose (SMBG)
Number of subjects: 64
Study 35842121 — intervention group
Group type: EXPERIMENTAL
Intervention: Ustekinumab
Number of subjects: 77
Study 33278504 — intervention group
Group type: EXPERIMENTAL
Intervention: Cathodal tDCS (n = 11)
Number of subjects: 25
Study 33278504 — intervention group
Group type: COMPARATOR
Intervention: Sham tDCS (n = 10)
Number of subjects: 25
Study 33278504 — intervention group
Group type: COMPARATOR
Intervention: Healthy volunteers (n = 10)
Number of subjects: 25
Study 33278504 — intervention group
Group type: EXPERIMENTAL
Intervention: Migraineurs (n = 25)
Number of subjects: 25
Study 32988518 — intervention group
Group type: EXPERIMENTAL
Intervention: Feeding frequency 3 times daily
Number of subjects: 240
Study 32988518 — intervention group
Group type: EXPERIMENTAL
Intervention: Feeding frequency 4 times daily
Number of subjects: 240
Study 32988518 — intervention group
Group type: COMPARATOR
Intervention: Ad libitum feeding
Number of subjects: 240
Study 32988518 — intervention group
Group type: EXPERIMENTAL
Intervention: Different feeding frequencies (3 to 5 times daily)
Number of subjects: 240
Study 32988518 — intervention group
Group type: EXPERIMENTAL
Intervention: Different feeding frequencies
Number of subjects: 240
Study 33211292 — intervention group
Group type: EXPERIMENTAL
Intervention: Farmed fish (Oreochromis niloticus)
Number of subjects: 208
Study 33211292 — intervention group
Group type: COMPARATOR
Intervention: Natural source fish (Prochilodus magdalenae and Pimelodus grosskopfii)
Number of subjects: 208
Study 33211292 — intervention group
Group type: EXPERIMENTAL
Intervention: Tissue types (stomach, gill, flesh)
Number of subjects: 208
Study 33211292 — intervention group
Group type: EXPERIMENTAL
Intervention: Identified microplastics
Number of subjects: 208
Study 36336624 — intervention group
Group type: EXPERIMENTAL
Intervention: Biophilic virtual reality (BVR)
Number of subjects: 106
Study 36336624 — intervention group
Group type: EXPERIMENTAL
Intervention: Indoor virtual reality (IVR)
Number of subjects: 106
Study 36336624 — intervention group
Group type: COMPARATOR
Intervention: Blank control group
Number of subjects: 106
Study 33449304 — intervention group
Group type: EXPERIMENTAL
Intervention: Capsaicinoids at 10 μmol/L
Number of subjects: 0
Study 33449304 — intervention group
Group type: EXPERIMENTAL
Intervention: Capsaicinoids preconditioning at 10 μmol/L over 5 min
Number of subjects: 0
Study 33449304 — intervention group
Group type: EXPERIMENTAL
Intervention: Capsaicinoids at 50 μmol/L
Number of subjects: 0
Study 33449304 — intervention group
Group type: COMPARATOR
Intervention: Non-carbonated water (control)
Number of subjects: 0
Study 32573158 — intervention group
Group type: EXPERIMENTAL
Intervention: Lumbosacral approach group
Number of subjects: 87
Study 32573158 — intervention group
Group type: COMPARATOR
Intervention: Buttock approach group
Number of subjects: 87
Study 34542698 — intervention group
Group type: EXPERIMENTAL
Intervention: Computed tomography (Pöschl projection) and subsequent dissection by milling
Number of subjects: 295
Study 34542698 — intervention group
Group type: EXPERIMENTAL
Intervention: Arcuate eminence classified as flat (1 mm)
Number of subjects: 295
Study 34542698 — intervention group
Group type: EXPERIMENTAL
Intervention: Arcuate eminence classified as prominent (1-2 mm)
Number of subjects: 295
Study 34542698 — intervention group
Group type: EXPERIMENTAL
Intervention: Arcuate eminence classified as very prominent (above 2 mm)
Number of subjects: 295
Study 32054513 — intervention group
Group type: EXPERIMENTAL
Intervention: Business card given to patients (group 1)
Number of subjects: 141
Study 32054513 — intervention group
Group type: COMPARATOR
Intervention: No business card given to patients (group 2)
Number of subjects: 141
Study 32845283 — intervention group
Group type: EXPERIMENTAL
Intervention: Telmisartan, 40 mg
Number of subjects: 210
Study 32845283 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 210
Study 36403036 — intervention group
Group type: EXPERIMENTAL
Intervention: Family Integrated Care (FICare)
Number of subjects: 230
Study 36403036 — intervention group
Group type: COMPARATOR
Intervention: Conventional care
Number of subjects: 230
Study 32049588 — intervention group
Group type: EXPERIMENTAL
Intervention: Minimal Repeats group (rarely experienced repeating stimuli on consecutive trials)
Number of subjects: 0
Study 32049588 — intervention group
Group type: COMPARATOR
Intervention: Frequent Repeats group (frequently presented with repeating stimuli on consecutive trials)
Number of subjects: 0
Study 35039595 — intervention group
Group type: EXPERIMENTAL
Intervention: 600 mg ibuprofen
Number of subjects: 20
Study 35039595 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 20
Study 35039595 — intervention group
Group type: EXPERIMENTAL
Intervention: 200 mg ibuprofen
Number of subjects: 20
Study 33588872 — intervention group
Group type: EXPERIMENTAL
Intervention: Chicken broth (CB)
Number of subjects: 14
Study 33588872 — intervention group
Group type: COMPARATOR
Intervention: Placebo soup
Number of subjects: 14
Study 616761523 — intervention group
Group type: EXPERIMENTAL
Intervention: Web-based training (online video modules, discussions, assessments)
Number of subjects: 71
Study 616761523 — intervention group
Group type: COMPARATOR
Intervention: Conventional training (1-day live training)
Number of subjects: 71
Study 616761523 — intervention group
Group type: EXPERIMENTAL
Intervention: Web-based training
Number of subjects: 71
Study 616761523 — intervention group
Group type: COMPARATOR
Intervention: Conventional training
Number of subjects: 71
Study 34345911 — intervention group
Group type: EXPERIMENTAL
Intervention: TCFA-positive patients (n=98)
Number of subjects: 550
Study 34345911 — intervention group
Group type: COMPARATOR
Intervention: TCFA-negative patients (n=292)
Number of subjects: 550
Study 34345911 — intervention group
Group type: EXPERIMENTAL
Intervention: TCFA
Number of subjects: 550
Study 36037744 — intervention group
Group type: COMPARATOR
Intervention: ST + PNF training
Number of subjects: 60
Study 36037744 — intervention group
Group type: COMPARATOR
Intervention: ST + PNF training + TEAS intervention
Number of subjects: 60
Study 34197764 — intervention group
Group type: EXPERIMENTAL
Intervention: CoronaVac 1.5 μg
Number of subjects: 550
Study 34197764 — intervention group
Group type: EXPERIMENTAL
Intervention: CoronaVac 3.0 μg
Number of subjects: 550
Study 34197764 — intervention group
Group type: EXPERIMENTAL
Intervention: CoronaVac 1.5 μg (phase 2)
Number of subjects: 550
Study 34197764 — intervention group
Group type: EXPERIMENTAL
Intervention: CoronaVac 3.0 μg (phase 2)
Number of subjects: 550
Study 34197764 — intervention group
Group type: COMPARATOR
Intervention: Alum only (control)
Number of subjects: 550
Study 34197764 — intervention group
Group type: EXPERIMENTAL
Intervention: All groups (safety profile)
Number of subjects: 550
Study 32920241 — intervention group
Group type: EXPERIMENTAL
Intervention: Outcome-based incentives
Number of subjects: 400
Study 32920241 — intervention group
Group type: EXPERIMENTAL
Intervention: Process-based incentives
Number of subjects: 400
Study 32920241 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination of outcome- and process-based incentives
Number of subjects: 400
Study 32920241 — intervention group
Group type: EXPERIMENTAL
Intervention: Choice-based incentives
Number of subjects: 400
Study 32920241 — intervention group
Group type: COMPARATOR
Intervention: Not applicable
Number of subjects: 400
Study 36078179 — intervention group
Group type: EXPERIMENTAL
Intervention: HRV-guided training (HRV-G)
Number of subjects: 21
Study 36078179 — intervention group
Group type: COMPARATOR
Intervention: Predefined training (PRED-G)
Number of subjects: 21
Study 36078179 — intervention group
Group type: EXPERIMENTAL
Intervention: Both HRV-G and PRED-G
Number of subjects: 21
Study 34225767 — intervention group
Group type: EXPERIMENTAL
Intervention: Vitamin D3 supplementation (4000 IU/day)
Number of subjects: 86
Study 34225767 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 86
Study 33538329 — intervention group
Group type: EXPERIMENTAL
Intervention: Online decision aid (counseling followed by the additional use of the decision aid)
Number of subjects: 51
Study 33538329 — intervention group
Group type: COMPARATOR
Intervention: Control group (counseling only)
Number of subjects: 51
Study 33538329 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 51
Study 32150232 — intervention group
Group type: EXPERIMENTAL
Intervention: Gabapentin up to 1200 mg/d, orally, with 9 medical management visits (20 minutes each)
Number of subjects: 96
Study 32150232 — intervention group
Group type: EXPERIMENTAL
Intervention: Gabapentin in high-alcohol withdrawal group
Number of subjects: 96
Study 32150232 — intervention group
Group type: COMPARATOR
Intervention: Placebo with 9 medical management visits (20 minutes each)
Number of subjects: 96
Study 32540236 — intervention group
Group type: EXPERIMENTAL
Intervention: Topical treatments for actinic keratosis
Number of subjects: 0
Study 32540236 — intervention group
Group type: EXPERIMENTAL
Intervention: DCE (Discrete Choice Experiment) at baseline and final post-treatment assessment
Number of subjects: 0
Study 34237313 — intervention group
Group type: EXPERIMENTAL
Intervention: nVNS (transcutaneous vagal nerve stimulation)
Number of subjects: 27
Study 34237313 — intervention group
Group type: COMPARATOR
Intervention: Sham nVNS
Number of subjects: 27
Study 34237313 — intervention group
Group type: EXPERIMENTAL
Intervention: nVNS (open-label phase)
Number of subjects: 27
Study 34237313 — intervention group
Group type: COMPARATOR
Intervention: Sham nVNS (open-label phase)
Number of subjects: 27
Study 36774110 — intervention group
Group type: EXPERIMENTAL
Intervention: 400 IU/d of supplemental cholecalciferol (vitamin D3)
Number of subjects: 98
Study 36774110 — intervention group
Group type: EXPERIMENTAL
Intervention: 1000 IU/d of supplemental cholecalciferol (vitamin D3)
Number of subjects: 98
Study 34319769 — intervention group
Group type: COMPARATOR
Intervention: Tamoxifen
Number of subjects: 23360
Study 34319769 — intervention group
Group type: EXPERIMENTAL
Intervention: Dietary Modification (Women's Health Initiative)
Number of subjects: 23360
Study 34319769 — intervention group
Group type: COMPARATOR
Intervention: Conjugated equine estrogen (Women's Health Initiative)
Number of subjects: 23360
Study 35387833 — intervention group
Group type: EXPERIMENTAL
Intervention: Mechanical thrombectomy (MT) alone
Number of subjects: 0
Study 35387833 — intervention group
Group type: COMPARATOR
Intervention: Mechanical thrombectomy (MT) with alteplase
Number of subjects: 0
Study 33048570 — intervention group
Group type: EXPERIMENTAL
Intervention: OurRelationship and ePREP online relationship programs
Number of subjects: 90
Study 33048570 — intervention group
Group type: COMPARATOR
Intervention: Control group (matched civilian sample)
Number of subjects: 90
Study 36212173 — intervention group
Group type: EXPERIMENTAL
Intervention: Dexmedetomidine (0.4 μg·kg‐1·h‐1 before and during anesthesia, 0.2 μg·kg‐1·h‐1 after induction)
Number of subjects: 100
Study 36212173 — intervention group
Group type: EXPERIMENTAL
Intervention: Dexmedetomidine
Number of subjects: 100
Study 36212173 — intervention group
Group type: COMPARATOR
Intervention: Normal Saline (NS)
Number of subjects: 100
Study 34043996 — intervention group
Group type: EXPERIMENTAL
Intervention: N95 mask without an exhalation valve
Number of subjects: 22
Study 34043996 — intervention group
Group type: EXPERIMENTAL
Intervention: N95 mask with an exhalation valve
Number of subjects: 22
Study 34043996 — intervention group
Group type: COMPARATOR
Intervention: Control (no mask)
Number of subjects: 22
Study 33339973 — intervention group
Group type: EXPERIMENTAL
Intervention: Periodontitis
Number of subjects: 0
Study 33339973 — intervention group
Group type: COMPARATOR
Intervention: Periodontal therapy
Number of subjects: 0
Study 35099429 — intervention group
Group type: EXPERIMENTAL
Intervention: Pilates exercises
Number of subjects: 44
Study 35099429 — intervention group
Group type: COMPARATOR
Intervention: Isometric exercises
Number of subjects: 44
Study 33114585 — intervention group
Group type: EXPERIMENTAL
Intervention: 35 g protein (MOD)
Number of subjects: 8
Study 33114585 — intervention group
Group type: EXPERIMENTAL
Intervention: 70 g protein (HIGH)
Number of subjects: 8
Study 35812118 — intervention group
Group type: EXPERIMENTAL
Intervention: Acupuncture arm 1
Number of subjects: 497
Study 35812118 — intervention group
Group type: EXPERIMENTAL
Intervention: Acupuncture arm 2
Number of subjects: 497
Study 35812118 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 497
Study 33867179 — intervention group
Group type: EXPERIMENTAL
Intervention: Sucralfate (20 mg/kg per dose up to 1 g)
Number of subjects: 100
Study 33867179 — intervention group
Group type: COMPARATOR
Intervention: Placebo solution
Number of subjects: 100
Study 33867179 — intervention group
Group type: EXPERIMENTAL
Intervention: Sucralfate
Number of subjects: 100
Study 33867179 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 100
Study 34706404 — intervention group
Group type: EXPERIMENTAL
Intervention: Mind Sound Resonance Technique (MSRT)
Number of subjects: 32
Study 34706404 — intervention group
Group type: COMPARATOR
Intervention: Supine Rest (SR)
Number of subjects: 32
Study 33225377 — intervention group
Group type: EXPERIMENTAL
Intervention: Eluvia
Number of subjects: 440
Study 33225377 — intervention group
Group type: COMPARATOR
Intervention: Zilver PTX
Number of subjects: 440
Study 35343425 — intervention group
Group type: EXPERIMENTAL
Intervention: School Feeding Program (SFP)
Number of subjects: 4500
Study 34810348 — intervention group
Group type: EXPERIMENTAL
Intervention: 4% articaine buccal infiltration
Number of subjects: 40
Study 34810348 — intervention group
Group type: COMPARATOR
Intervention: 2% lidocaine inferior alveolar nerve block
Number of subjects: 40
Study 32867790 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral contraceptives containing cyproterone acetate (CPA)
Number of subjects: 200
Study 32867790 — intervention group
Group type: COMPARATOR
Intervention: Oral contraceptives containing desogestrel (DSG)
Number of subjects: 200
Study 32867790 — intervention group
Group type: COMPARATOR
Intervention: Oral contraceptives containing drospirenone (DRSP)
Number of subjects: 200
Study 32867790 — intervention group
Group type: COMPARATOR
Intervention: Oral contraceptives containing levonorgestrel (LNG)
Number of subjects: 200
Study 34923493 — intervention group
Group type: EXPERIMENTAL
Intervention: 1-year lifestyle programme focusing on a largely plant-based diet, physical activity, stress management, and community support
Number of subjects: 201
Study 34923493 — intervention group
Group type: COMPARATOR
Intervention: Control group (no intervention)
Number of subjects: 201
Study 34923493 — intervention group
Group type: EXPERIMENTAL
Intervention: 1-year lifestyle programme
Number of subjects: 201
Study 32299659 — intervention group
Group type: EXPERIMENTAL
Intervention: Multimodal educational intervention
Number of subjects: 82
Study 32299659 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 82
Study 32299659 — intervention group
Group type: EXPERIMENTAL
Intervention: Experimental group
Number of subjects: 82
Study 32171186 — intervention group
Group type: EXPERIMENTAL
Intervention: Targeted skin products
Number of subjects: 150
Study 32171186 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 150
Study 35653287 — intervention group
Group type: EXPERIMENTAL
Intervention: Best double variant I97L/G195A
Number of subjects: 0
Study 34158383 — intervention group
Group type: EXPERIMENTAL
Intervention: Bedside rounding
Number of subjects: 79
Study 34158383 — intervention group
Group type: COMPARATOR
Intervention: Hallway rounding
Number of subjects: 79
Study 34158383 — intervention group
Group type: COMPARATOR
Intervention: Residents' perception of hallway rounding
Number of subjects: 79
Study 34158383 — intervention group
Group type: EXPERIMENTAL
Intervention: Nurses' perception of bedside rounds
Number of subjects: 79
Study 34158383 — intervention group
Group type: COMPARATOR
Intervention: Patients' views on rounding
Number of subjects: 79
Study 35384807 — intervention group
Group type: EXPERIMENTAL
Intervention: Structured education (Group 1, n = 140)
Number of subjects: 210
Study 35384807 — intervention group
Group type: COMPARATOR
Intervention: Conventional education (Group 2, n = 70)
Number of subjects: 210
Study 33787345 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral prednisone at a dose of 1 mg/kg/day followed by weekly stepwise tapering in steps of 10 mg/day
Number of subjects: 155
Study 33787345 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 155
Study 33787345 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral prednisone
Number of subjects: 155
Study 32952824 — intervention group
Group type: EXPERIMENTAL
Intervention: Ivermectin administration over seven years
Number of subjects: 310
Study 32952824 — intervention group
Group type: EXPERIMENTAL
Intervention: Ivermectin administration
Number of subjects: 310
Study 36324229 — intervention group
Group type: EXPERIMENTAL
Intervention: Interferon β‐1a (7.5–30 μg)
Number of subjects: 84
Study 36324229 — intervention group
Group type: EXPERIMENTAL
Intervention: Pegylated interferon β‐1a (31.25–125 μg)
Number of subjects: 84
Study 33399860 — intervention group
Group type: EXPERIMENTAL
Intervention: Underreporting multipliers derived from CDC seroprevalence studies
Number of subjects: 100368
Study 33399860 — intervention group
Group type: COMPARATOR
Intervention: Reported COVID-19 infections adjusted using underreporting multipliers
Number of subjects: 100368
Study 35422071 — intervention group
Group type: EXPERIMENTAL
Intervention: Piezocision procedure
Number of subjects: 16
Study 35422071 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 16
Study 33811354 — intervention group
Group type: EXPERIMENTAL
Intervention: Chinese version of the Baby Eating Behaviour Questionnaire (BEBQ)
Number of subjects: 300
Study 32366799 — intervention group
Group type: EXPERIMENTAL
Intervention: Positive preexercise information
Number of subjects: 83
Study 32366799 — intervention group
Group type: EXPERIMENTAL
Intervention: Negative preexercise information
Number of subjects: 83
Study 32366799 — intervention group
Group type: COMPARATOR
Intervention: Neutral preexercise information
Number of subjects: 83
Study 35259753 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-Level Laser Therapy (LLLT)
Number of subjects: 45
Study 35259753 — intervention group
Group type: EXPERIMENTAL
Intervention: Electrical Stimulation (E.S.)
Number of subjects: 45
Study 35259753 — intervention group
Group type: COMPARATOR
Intervention: Control (Medication, massage, and facial exercise)
Number of subjects: 45
Study 32212009 — intervention group
Group type: EXPERIMENTAL
Intervention: Phenytoin
Number of subjects: 66
Study 32212009 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 66
Study 35716984 — intervention group
Group type: EXPERIMENTAL
Intervention: ChloraPrep™ (2% chlorhexidine gluconate and 70% isopropyl alcohol)
Number of subjects: 30
Study 35716984 — intervention group
Group type: COMPARATOR
Intervention: Betadine® Surgical Scrub and Betadine® 5% solution (povidone‐iodine)
Number of subjects: 30
Study 33038832 — intervention group
Group type: COMPARATOR
Intervention: Omega-3 LCPUFA supplementation
Number of subjects: 5544
Study 33038832 — intervention group
Group type: COMPARATOR
Intervention: Control (no omega-3 LCPUFA supplementation)
Number of subjects: 5544
Study 36209067 — intervention group
Group type: EXPERIMENTAL
Intervention: Group Schema Therapy (GST)
Number of subjects: 378
Study 36209067 — intervention group
Group type: COMPARATOR
Intervention: Individual Schema Therapy (IST)
Number of subjects: 378
Study 36209067 — intervention group
Group type: COMPARATOR
Intervention: Treatment as Usual (TAU)
Number of subjects: 378
Study 36209067 — intervention group
Group type: EXPERIMENTAL
Intervention: Severity of Cluster-C PD
Number of subjects: 378
Study 36209067 — intervention group
Group type: EXPERIMENTAL
Intervention: Functioning and wellbeing
Number of subjects: 378
Study 32409778 — intervention group
Group type: EXPERIMENTAL
Intervention: Home/community-based exercise intervention for 6 months
Number of subjects: 84
Study 32409778 — intervention group
Group type: COMPARATOR
Intervention: Wait-List Control
Number of subjects: 84
Study 32409778 — intervention group
Group type: EXPERIMENTAL
Intervention: Home/community-based exercise intervention
Number of subjects: 84
Study 34588153 — intervention group
Group type: EXPERIMENTAL
Intervention: Web-based and machine learning approaches for identifying patient-reported outcomes
Number of subjects: 20
Study 33210508 — intervention group
Group type: EXPERIMENTAL
Intervention: J‐pouch surgery
Number of subjects: 90
Study 33210508 — intervention group
Group type: COMPARATOR
Intervention: Side‐to-end anastomoses (S‐E)
Number of subjects: 90
Study 33210508 — intervention group
Group type: COMPARATOR
Intervention: End‐to‐end anastomoses (E‐E)
Number of subjects: 90